Corient Private Wealth LLC Cuts Holdings in Stryker Corporation $SYK

Corient Private Wealth LLC lowered its position in Stryker Corporation (NYSE:SYK) by 14.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 811,526 shares of the medical technology company’s stock after selling 138,467 shares during the period. Corient Private Wealth LLC’s holdings in Stryker were worth $275,370,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of SYK. Godfrey Financial Associates Inc. acquired a new position in Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter valued at approximately $27,000. DJE Kapital AG purchased a new stake in shares of Stryker in the fourth quarter valued at approximately $28,000. Finally, CGC Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $29,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SYK shares. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 target price on shares of Stryker in a research report on Wednesday, March 4th. JPMorgan Chase & Co. cut their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Barclays dropped their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Finally, Truist Financial reissued a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Trading Up 2.5%

SYK opened at $308.62 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company’s 50 day simple moving average is $314.43 and its two-hundred day simple moving average is $341.94. The firm has a market capitalization of $118.31 billion, a price-to-earnings ratio of 35.72, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.